Saturday 17 October 2026 Export AXSM’s income statement to Excel — free account

Axsome Therapeutics, Inc.

Axsome Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $638.5 million, up 65.5% from fiscal 2024. In the quarter to June 2026, revenue grew 45.5%, EPS fell 2.06%, free cash flow fell 2.98% and total debt rose 4.66%, each against the same quarter a year earlier. Revenue growth for three consecutive years.

157.14 4.65 −2.87%

Follow AXSM

Alert me

Market cap: $8.5B
P/E: 0.0×
Fwd P/E: −121×
Dividend yield: —
F-score: 5/9
Altman Z: 6.91
Beneish M: −2.53
Dividend safety: n/a

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Total sells 134.33

Totals in millions of $.

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	—	—	—	—	—	—	—	—	—	—	—
Sell	1	2	3	3	—	1	2	5	1	1	1	—

Insider Ownership 14.71%

Capital & Financial Ratios $m

Market Cap 8,470.00

Revenue 776.57

Net Income (191.64)

Free Cash Flow (71.96)

Net Debt (192.86)

Current Ratio 1.43

Debt/Equity 1.52

P/E ratio 0.00

Fwd P/E (121.00)

P/S ratio 10.48

P/B ratio 97.71

Past 5Y EPS Growth —

This Y EPS Growth 21.51%

Next Y EPS Growth 237.01%

Next Y revenue growth 49.19%

Next 5Y EPS Growth —

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years

P/S against its own 10 years 2.25%

10-year low 10-year high

P/B against its own 10 years 81.57%

10-year low 10-year high

EV/Sales against its own 10 years 3.15%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

	total	individual payouts
2025	Powerpack
2024	Powerpack
2023	Powerpack
2022	Powerpack
2021	Powerpack
2020	Powerpack
2019	Powerpack
2017	Powerpack

predictions special payouts not included in total or ratios

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	386	315	323	320
Receivables	95	142	224	277
Inventory	15	16	28	38
Other	—	—	—	—
	504	485	589	657

	2023	2024	2025	Q'26
Payables	41	72	66	79
ST’ Debt	—	—	—	—
Other	6	8	10	11
	139	230	379	460

Compound Annual Growth %

	10y	5y	3y
Sales	—	—	133.68%
Cash Flow	0.00%	0.00%	0.00%
Earnings	0.00%	0.00%	0.00%
Book Value	6.64%	(4.95%)	(6.94%)

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	191	218	—	—	—
’25	121	150	171	196	638
’24	75	87	105	119	386
’23	95	47	58	72	271

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(21)	(33)	—	—	—
’25	(43)	(32)	1	(19)	(93)
’24	(53)	(30)	(19)	(26)	(128)
’23	(6)	(55)	(54)	(30)	(145)
’22	(33)	(34)	(23)	(28)	(117)
’21	(27)	(25)	(27)	(29)	(108)
’20	(23)	(19)	(16)	(21)	(78)

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(21)	(33)	—	—	—
’25	(44)	(32)	1	(19)	(94)
’24	(54)	(30)	(19)	(26)	(129)
’23	(6)	(55)	(54)	(30)	(146)
’22	(33)	(34)	(23)	(28)	(117)
’21	(27)	(25)	(27)	(29)	(109)
’20	(23)	(19)	(16)	(21)	(79)

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	(1.26)	(0.99)	—	—	—
’25	(1.22)	(0.97)	(0.94)	(0.56)	(3.68)
’24	(1.44)	(1.67)	(1.34)	(1.54)	(5.99)
’23	(0.26)	(1.54)	(1.32)	(2.08)	(5.27)
’22	(1.03)	(1.06)	(1.07)	(1.41)	(4.60)
’21	(0.78)	(0.86)	(0.93)	(0.90)	(3.47)
’20	(0.88)	(0.49)	(0.61)	(0.78)	(2.77)

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e
Price, $
Price, $	Low	5.25	3.53	1.94	2.52	35.44	19.38	20.63	53.71	64.11	79.19	Analyst estimates 2026–2028 Powerpack
	High	15.74	7.10	5.76	109.94	109.53	82.98	82.00	91.29	105.00	184.40
People
People	Employees	22	25	29	45	60	108	383	545	683	925
	Revenue/emp, $m	0.00	0.00	0.00	0.00	0.00	0.00	0.13	0.50	0.56	0.69
Income, $m
Income, $m	Revenue	—	—	—	—	—	—	50	271	386	638
	Gross margin, %	0.00	0.00	0.00	0.00	0.00	0.00	89.61	90.37	91.37	92.56
	EBT	(27)	(29)	(31)	(68)	(103)	(130)	(187)	(238)	(287)	(184)
	EBT margin, %	0.00	0.00	0.00	0.00	0.00	0.00	(373.99)	(88.06)	(74.45)	(28.77)
	Net income	(27)	(29)	(31)	(68)	(103)	(130)	(187)	(239)	(287)	(183)
	Depreciation	0	1	0	1	1	1	6	9	11	10
Per share, $
Per share, $	Revenue	0.00	0.00	0.00	0.00	0.00	0.00	1.23	5.96	8.05	12.83
	Earnings	(1.42)	(1.27)	(1.15)	(2.01)	(2.77)	(3.47)	(4.60)	(5.27)	(5.99)	(3.68)
	Cash flow	(1.11)	(1.16)	(1.12)	(1.36)	(2.11)	(2.88)	(2.87)	(3.19)	(2.68)	(1.88)
	Capex	(0.01)	0.00	0.00	0.00	0.00	(0.01)	(0.02)	(0.01)	(0.01)	(0.01)
	Free cash flow	(1.12)	(1.16)	(1.12)	(1.36)	(2.11)	(2.89)	(2.88)	(3.21)	(2.69)	(1.89)
	Book value	1.13	0.73	0.03	5.25	3.06	0.42	2.69	4.20	1.19	1.77
	Shares, m	19	23	27	34	37	38	41	45	48	50
Valuation, ×
Valuation, ×	P/E	—	—	—	—	—	—	0.00	0.00	0.00	0.00
	P/S	—	—	—	—	—	—	0.00	12.94	10.51	14.23
	P/B	—	—	—	—	—	—	27.21	18.33	71.10	102.90
	EV/Sales	—	—	—	—	—	—	0.00	12.17	10.17	13.92
	EV/FCF	—	—	—	—	—	—	(24.53)	(22.61)	(30.49)	(94.64)
Cash, $m
Cash, $m	Operating cash flow	(21)	(26)	(30)	(46)	(78)	(108)	(117)	(145)	(128)	(93)
	Capex	0	0	0	0	0	0	(1)	(1)	0	0
	Free cash flow	(21)	(26)	(30)	(46)	(79)	(109)	(117)	(146)	(129)	(94)
Balance, $m
Balance, $m	Working capital	31	23	4	196	161	63	149	365	255	210
	Total debt	9	7	4	17	48	49	94	178	184	122
	Net debt	(27)	(27)	(10)	(203)	(136)	(37)	(107)	(208)	(132)	(201)
	Shareholders’ equity	22	17	1	179	114	16	110	191	57	88
Returns, %
Returns, %	ROA	(62.33)	(78.47)	(121.59)	(57.94)	(50.60)	(95.21)	(89.27)	(52.02)	(49.66)	(29.11)
	ROIC	0.00	0.00	0.00	0.00	0.00	0.00	(3,779.83)	0.00	0.00	0.00
	ROE	(79.99)	(151.19)	(350.78)	(76.08)	(70.36)	(201.51)	(298.97)	(159.21)	(231.63)	(252.11)

Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
KYMR Kymera Therapeutics, Inc.	$9.0B	— (loss-making)	— (loss-making)	+466.40% (above 0%: growing)	n/m	+9.97% (above 0%: growing)	100.00%	(116.32%)	Compare
CAI Caris Life Sciences,�Inc.	$9.0B	81.3×	163×	+45.38% (above 0%: growing)	n/m	+8.47% (above 0%: growing)	68.10%	10.21%	Compare
CYTK Cytokinetics, Incorporated	$8.9B	— (loss-making)	— (loss-making)	−57.13% (below 0%: shrinking)	n/m	−24.02% (below 0%: shrinking)	80.46%	(625.95%)	Compare
PTGX Protagonist Therapeutics, Inc.	$8.8B	106×	25.0×	+3,749.17% (above 0%: growing)	n/m	+839.65% (above 0%: growing)	100.00%	74.37%	Compare
TGTX TG Therapeutics, Inc.	$8.6B	17.8×	29.4×	+70.27% (above 0%: growing)	−73.68% (below 0%: shrinking)	+427.05% (above 0%: growing)	82.86%	9.02%	Compare
AXSM Axsome Therapeutics, Inc.	$8.5B	— (loss-making)	— (loss-making)	+45.54% (above 0%: growing)	n/m	−2.98% (below 0%: shrinking)	93.79%	(22.73%)
ARWR Arrowhead Pharmaceuticals, Inc.	$8.3B	— (loss-making)	— (loss-making)	+171.02% (above 0%: growing)	n/m	−15.43% (below 0%: shrinking)	100.00%	(226.03%)	Compare
ABVX Abivax SA Sponsored ADR	$8.1B	— (loss-making)	—	—	n/m	−48.28% (below 0%: shrinking)	0.00%	0.00%	Compare
SYRE Spyre Therapeutics, Inc.	$7.4B	— (loss-making)	— (loss-making)	−100.00% (below 0%: shrinking)	n/m	−50.07% (below 0%: shrinking)	0.00%	0.00%	Compare
Median of peers	$8.7B	81.3×	29.4×	+70.27%	—	−3.48%	81.66%	0.00%

All 614 Biotechnology stocks →

Axsome Therapeutics, Inc. (AXSM) key facts

Concern: Axsome Therapeutics, Inc. reported a net loss of $183.2 million, or a loss of $3.68 per share, for fiscal 2025.
Strength: Axsome Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $638.5 million, up 65.5% from fiscal 2024.
Axsome Therapeutics, Inc. (AXSM) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
As of October 16, 2026, AXSM traded at $157.14, a market capitalization of $8.5 billion.
Trailing earnings are negative, so a P/E ratio is not meaningful; the stock trades at 10.5× sales.
Return on equity was −252.1% and debt-to-equity 1.52.
Its Piotroski F-score is 5 out of 9 and its Altman Z-score is 6.91 (safe zone) for fiscal 2025.